hepatocellular carcinoma ( hcc , also call hepatoma ) primari malign ( cancer ) liver . case hcc secondari either hepat infect ( usual hepat b c ) cirrhosi ( alcohol common caus hepat cirrhosi ) . countri hepat endem , malign cancer liver primari hcc metastasi ( spread ) cancer elsewher bodi , e.g . colon . treatment option hcc prognosi depend mani factor especi tumor size stage . outsid west , commonli accept prognosi median surviv 3 month diagnosi . partial due late present larg tumour , also lack medic expertis facil . # # epidemiolog epidemiolog hcc exhibit two main pattern , one north america western europ anoth non-western countri ( region sub-saharan africa , central asia , southeast asia , amazon basin ) . # # # non-western countri part world , sub-saharan africa southeast asia ( especi taiwan china ) hcc common cancer , gener affect men woman , age onset late teen 30 's . variabl part due differ pattern hepat b transmiss differ popul - infect around birth ( taiwan ) predispos earlier cancer peopl infect later . time hepat b infect develop hcc year even decad , diagnosi hcc death averag surviv period 5.9 month , accord one chines studi 1970-80 , 3 month ( median surviv time ) sub-saharan africa accord manson 's textbook tropic diseas . hcc one deadliest cancer china . food infect aspergillu flavu ( especi peanut corn store prolong wet season ) produc aflatoxin , pose anoth risk factor hcc . # # # north america western europ malign tumor liver discov western patient metastasi ( spread ) tumor elsewher . west , hcc gener seen rare cancer , normal pre-exist liver diseas . often detect ultrasound screen , discov health-car facil much earlier develop region sub-saharan africa . acut chronic hepat porphyria ( acut intermitt porphyria , porphyria cutanea tarda , hereditari coproporphyria , varieg porphyria ) tyrosinemia type risk factor hepatocellular carcinoma . diagnosi acut hepat porphyria ( aip , hcp , vp ) sought patient hepatocellular carcinoma without typic risk factor hepat b c , alcohol liver cirrhosi hemochromatosi . activ latent genet carrier acut hepat porphyria risk cancer , although latent genet carrier develop cancer later age classic symptom . patient acut hepat porphyria monitor hepatocellular carcinoma . # # diagnosi , screen monitor hepatocellular carcinoma ( hcc ) commonli appear patient chronic viral hepat ( hepat b hepat c , 20 % ) cirrhosi ( 80 % ) . patient commonli undergo surveil ultrasound due cost-effect . patient higher suspicion hcc ( rise alpha-fetoprotein level ) , best method diagnosi involv ct scan abdomen use intraven contrast agent three-phas scan ( contrast administr , immedi contrast administr , delay ) increas abil radiologist detect small subtl tumor . import optim paramet ct examin , underli liver diseas hcc patient make find difficult appreci . ct , hcc three distinct pattern growth : singl larg tumor multipl tumor poorli defin tumor infiltr growth pattern calcif intralesion fat may appreci . patient contrast agent allergi poor renal function , mri scan abdomen costli effect substitut . imag , diagnosi confirm percutan biopsi histopatholog analysi . # # patholog macroscop , liver cancer appear nodular infiltr tumor . nodular type may solitari ( larg mass ) multipl ( develop complic cirrhosi ) . tumor nodul round oval , grey green ( tumor produc bile ) , well circumscrib encapsul . diffus type poorli circumscrib infiltr portal vein , hepat vein ( rare ) . microscop , four architectur cytolog type ( pattern ) hepatocellular carcinoma : fibrolamellar , pseudoglandular ( adenoid ) , pleomorph ( giant cell ) clear cell . well differenti form , tumor cell resembl hepatocyt , form trabecula , cord nest , may contain bile pigment cytoplasm . poorli differenti form , malign epitheli cell discohes , pleomorph , anaplast , giant . tumor scant stroma central necrosi poor vascular . 1 # # stage prognosi import featur guid treament includ : - size spread ( stage ) involv liver vessel presenc tumor capsul presenc extrahepat metastasi presenc daughter nodul vascular tumor mri best imag method detect presenc tumor capsul . xx # # treatment liver transplant replac liver cadav liver live donor lobe . histor low surviv rate ( 20 % -36 % ) recent improv ( 61.1 % ; 1996-2001 ) , like relat adopt milan criterion us transplant center . tumor diseas metastas , immuno-suppres post-transpl drug decreas chanc surviv . nih surgic resect remov tumor treat small slow-grow tumor diagnos earli . treatment offer best prognosi long-term surviv unfortun possibl 10-15 % case . resect cirrhot patient carri high morbid mortal . medicinenet percutan ethanol inject ( pei ) pei well toler , high rr small ( < 3 cm ) solitari tumor ; 2005 , random trial compar resect percutan treatment ; recurr rate similar postresect . transcathet arteri chemoembol ( tace ) usual perform treatment larg tumor ( larger 3 cm less 4 cm diamet ) frequent perform intraarteri inject infus antineoplast agent mix iodiz oil ( lipiodol ) . 2005 , multipl trial show object tumor respons slow tumor progress question surviv benefit compar support care ; greatest benefit seen patient preserv liver function , absenc vascular invas , smallest tumor . radiofrequ ablat ( rfa ) us high frequenc radio-wav ablat tumour . intra-arteri iodine-131–lipiodol administr efficaci demonstr unresect patient , portal vein thrombu . treatment also use adjuv therapi resect patient ( lau et , 1999 ) . believ rais 3-year surviv rate 46 86 % . adjuv therapi phase iii clinic trial singapor avail standard medic treatment qualifi patient hong kong . combin pei tace use tumor larger 4 cm diamet , although italian group success larger tumour use tace alon . high intens focus ultrasound ( hifu ) ( confus normal diagnost ultrasound ) new techniqu us much power ultrasound treat tumour . still experiment stage . work done china . earli work done oxford london uk . hormon therapi antiestrogen therapi tamoxifen studi sever trial , mix result across studi , gener consid ineffect octreotid ( somatostatin analogu ) show 13-month ms v 4-month ms untreat patient small random studi ; result reproduc chemotherapi adjuv : random trial show benefit neoadjuv adjuv system therapi hcc ; singl trial show decreas new tumor patient receiv oral synthet retinoid 12 month resection/ ablat ; result reproduc . clinic trial vari result .. palli : regimen includ doxorubicin , cisplatin , fluorouracil , interferon , epirubicin , taxol , singl agent combin , shown surviv benefit ( rr , 0 % -25 % ) ; isol major respons allow patient undergo partial hepatectomi ; publish result random trial system chemotherapi cryosurgeri : cryosurgeri new techniqu destroy tumor varieti site ( brain , breast , kidney , prostat , liver ) . cryosurgeri destruct abnorm tissu use sub-zero temperatur . tumor remov destroy cancer left reabsorb bodi . initi result properli select patient unresect liver tumor equival resect . cryosurgeri involv placement stainless steel probe centr tumor . liquid nitrogen circul end devic . tumor half inch margin normal liver frozen -190°c 15 minut , lethal tissu . area thaw 10 minut re-frozen -190°c anoth 15 minut . tumor thaw , probe remov , bleed control , procedur complet . patient spend first post-op night intens care unit typic discharg 3 - 5 day . proper select patient attent detail perform cryosurg procedur mandatori order achiev good result outcom . frequent , cryosurgeri use conjunct liver resect tumor remov other treat cryosurgeri . patient may also insert hepat intra-arteri arteri cathet post-op chemotherapi . liver resect , surgeon experi cryosurg techniqu order provid best treatment possibl . intervent radiolog abbrevi : hcc , hepatocellular carcinoma ; tace , transarteri embolization/chemoembol ; pf , progression-fre surviv ; ps , perform statu ; hbv , hepat b viru ; pei , percutan ethanol inject ; rr , respons rate ; ms , median surviv . # # futur direct current research includ search gene disregul hcc , protein marker , predict biomark . . similar research yield result variou malign diseas , hope identifi aberr gene result protein could lead identif pharmacolog intervent hcc .